Prospective Evaluation of Patients With Uterine Cervical Cancer in Brazilian Health Institutions - The EVITA I Study
The primary objective of this study is to describe the socio-demographic, clinical pathological, quality of life and treatment characteristics of patients diagnosed with CC in Brazil.
Cervix Cancer
BEHAVIORAL: Quality of Life Questionnaire (QLQ)
Characterization of cervix cancer in the Brazilian female population, 3 years
Socio-demographic characteristics of the female population diagnosed with CC, Month 0 (beginning of the study)|Description of the method used to diagnose the brazillian female patients with cervix cancer, Screening tests (Papanicolaou test) or symptoms presented by patients, Month 0|The clinical and pathological characteristics of cervix cancer in brazilian female patients, Month 0|Type of treatment assessed in patients with CC, Radiotherapy, Chemotherapy and/or Surgery, Month 0, 3, 6,12, 24 and 36|Number of patients with disease survival, Month 3, 6, 12, 24 and 36|Number of patients with progression survival, Month 3, 6, 12, 24 and 36|Number of patients with overall survival, Month 3, 6, 12, 24 and 36|Number of patients with disease overall survival, Month 3, 6, 12, 24 and 36|Type and description of the indicated treatment after the diagnosis of cervix cancer in brazilian female patients, Month 0, 3, 6,12, 24 and 36|Duration of treatment after the diagnosis of cervix cancer, Month 0, 3, 6,12, 24 and 36|Description of adverse effects of the cervix cancer treatment, Month 0, 3, 6,12, 24 and 36|Number of adverse effects of the cervix cancer treatment, Month 0, 3, 6,12, 24 and 36|Type of clinical outcomes of the patients with cervix cancer in Brazil, Month 0, 3, 6,12, 24 and 36
The primary objective of this study is to describe the socio-demographic, clinical pathological, quality of life and treatment characteristics of patients diagnosed with cervix cancer (CC) in Brazil. Other specific objectives are:

* To describe socio-demographic characteristics: age at diagnosis, education, family income, race, occupation, personal health habits - e.g.oral contraceptive use ever/never and duration; smoking never/ever/current/duration , ever drinking), sexual history, insurance coverage (private, public), institution (private, public, philanthropic), obstetric history, comorbidities, performance status, human papillomavirus vaccination or not
* To describe the screening for CC: access, type, frequency and results.
* To describe clinical pathological characteristics of CC: histology (adeno x squamous x adenosquamous x neuroendocrine x other) , International Federation of Gynecology and Obstetrics (FIGO) stage, pathological stage, exams for staging, date of diagnosis, site of metastasis.
* To describe treatment characteristics of CC: date of surgery, type of surgery; date and duration of radiotherapy, type of radiotherapy; date, type and lines of systemic therapy (chemotherapy, monoclonal antibodies),
* To describe treatment safety (grade 3-4 AEs, death due to treatment toxicity, discontinuation due to AE). In addition adverse events of special interest will be described (details on Safety section).
* To describe the outcomes: follow-up exams and date of visits, persistent disease, recurrence, progression times in metastatic disease, complications (e.g. hydronephrosis/nephrostomy/ GI perforations and both GI \& genitourinary fistulae.), death due CC and death from any cause.